Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

808 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma.
Weisberg E, Chowdhury B, Meng C, Case AE, Ni W, Garg S, Sattler M, Azab AK, Sun J, Muz B, Sanchez D, Toure A, Stone RM, Galinsky I, Winer E, Gleim S, Gkountela S, Kedves A, Harrington E, Abrams T, Zoller T, Vaupel A, Manley P, Faller M, Chung B, Chen X, Busenhart P, Stephan C, Calkins K, Bonenfant D, Thoma CR, Forrester W, Griffin JD. Weisberg E, et al. Among authors: winer e. Blood Cancer J. 2022 Jul 19;12(7):110. doi: 10.1038/s41408-022-00704-7. Blood Cancer J. 2022. PMID: 35853853 Free PMC article.
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2.
Yang J, Weisberg EL, Liu X, Magin RS, Chan WC, Hu B, Schauer NJ, Zhang S, Lamberto I, Doherty L, Meng C, Sattler M, Cabal-Hierro L, Winer E, Stone R, Marto JA, Griffin JD, Buhrlage SJ. Yang J, et al. Among authors: winer e. Leukemia. 2022 Jan;36(1):210-220. doi: 10.1038/s41375-021-01336-9. Epub 2021 Jul 29. Leukemia. 2022. PMID: 34326465
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, Stein AS, Stone RM, Winer ES, Seet CS, Döhner H, Pollyea DA, McCloskey JK, Odenike O, Löwenberg B, Ossenkoppele GJ, Patel PA, Roshal M, Frattini MG, Lersch F, Franovic A, Nabhan S, Fan B, Choe S, Wang H, Wu B, Hua L, Almon C, Cooper M, Kantarjian HM, Tallman MS. Stein EM, et al. Blood. 2021 Apr 1;137(13):1792-1803. doi: 10.1182/blood.2020007233. Blood. 2021. PMID: 33024987 Free PMC article. Clinical Trial.
Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax.
Chen EC, Liu Y, Harris CE, Winer ES, Wadleigh M, Lane AA, Vedula RS, Lindsley RC, Copson KM, Charles A, Marty F, Neuberg D, DeAngelo DJ, Stone RM, Luskin MR, Issa NC, Garcia JS. Chen EC, et al. Among authors: winer es. Leuk Lymphoma. 2022 Aug;63(8):1934-1941. doi: 10.1080/10428194.2022.2047964. Epub 2022 Mar 15. Leuk Lymphoma. 2022. PMID: 35289704 Free PMC article.
BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target Genes.
Schaefer EJ, Wang HC, Karp HQ, Meyer CA, Cejas P, Gearhart MD, Adelman ER, Fares I, Apffel A, Lim K, Xie Y, Gibson CJ, Schenone M, Murdock HM, Wang ES, Gondek LP, Carroll MP, Vedula RS, Winer ES, Garcia JS, Stone RM, Luskin MR, Carr SA, Long HW, Bardwell VJ, Figueroa ME, Lindsley RC. Schaefer EJ, et al. Among authors: winer es. Blood Cancer Discov. 2022 Mar 1;3(2):116-135. doi: 10.1158/2643-3230.BCD-21-0115. Blood Cancer Discov. 2022. PMID: 35015684 Free PMC article.
Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms.
Van Egeren D, Kamaz B, Liu S, Nguyen M, Reilly CR, Kalyva M, DeAngelo DJ, Galinsky I, Wadleigh M, Winer ES, Luskin MR, Stone RM, Garcia JS, Hobbs GS, Michor F, Cortes-Ciriano I, Mullally A, Hormoz S. Van Egeren D, et al. Exp Hematol. 2022 Mar;107:14-19. doi: 10.1016/j.exphem.2021.12.364. Epub 2021 Dec 15. Exp Hematol. 2022. PMID: 34921959 Free PMC article.
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial.
Brunner AM, Blonquist TM, DeAngelo DJ, McMasters M, Fell G, Hermance NM, Winer ES, Lindsley RC, Hobbs GS, Amrein PC, Hock HR, Steensma DP, Garcia JS, Luskin MR, Stone RM, Ballen KK, Rosenblatt J, Avigan D, Nahas MR, Mendez LM, McAfee SL, Moran JA, Bergeron M, Foster J, Bertoli C, Manning AL, McGregor KL, Fishman KM, Kuo FC, Baltay MT, Macrae M, Burke M, Behnan T, Wey MC, Som TT, Ramos AY, Rae J, Lombardi Story J, Nelson N, Logan E, Connolly C, Neuberg DS, Chen YB, Graubert TA, Fathi AT. Brunner AM, et al. Among authors: winer es. Lancet Haematol. 2020 Feb;7(2):e122-e133. doi: 10.1016/S2352-3026(19)30203-0. Epub 2019 Dec 11. Lancet Haematol. 2020. PMID: 31837959 Free PMC article. Clinical Trial.
808 results